Cargando…

P081: Cefepime-tazobactam: a new antibiotic against ESBL producing enterobacteriaceae in cancer patients

Detalles Bibliográficos
Autores principales:	Biswas, S, Kelkar, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688241/ http://dx.doi.org/10.1186/2047-2994-2-S1-P81

Ejemplares similares

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

Prevalence of carriage of ESBL producing enterobacteriaceae in a Dutch teaching hospital
por: Moen, G, et al.
Publicado: (2011)

260 Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
por: Popejoy, Myra, et al.
Publicado: (2014)

P078: Epidemiology of extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBL-E) during an epidemic, with screening of patients and healthcare workers
por: Agostinho, A, et al.
Publicado: (2013)

Prevalence of extended-spectrum betalactamase producing–Enterobacteriaceae (ESBL-E) carriage on admission at Geneva University Hospitals (HUG)
por: Fankhauser, C, et al.
Publicado: (2015)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

Trends in extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae and ESBL genes in a Dutch teaching hospital, measured in 5 yearly point prevalence surveys (2010-2014)
por: Willemsen, I, et al.
Publicado: (2015)

1409. Evaluation of Alternative Piperacillin–tazobactam Dosing Strategies Against ESBL-Producing Enterobacteriaceae Using a Hollowfiber Infection Model
por: Abodakpi, Henrietta, et al.
Publicado: (2018)

P081 Experiences of men who have had bariatric surgery in New Zealand
por: Besley, E
Publicado: (2023)

Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
por: Wang, Ruibin, et al.
Publicado: (2016)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

80. Pharmacoeconomic Analysis Comparing the Empiric Utilization of Cefepime Versus Piperacillin/tazobactam
por: Olmack, Kelsey, et al.
Publicado: (2020)

P-081: EVALUATION OF THE SEXUALITY OF ADULT HOMOZYGOUS SICKLE CELL PATIENTS WITH A HISTORY OF PRIAPISM IN SENEGAL
por: M., SECK, et al.
Publicado: (2022)

P081 Assessing the role of mental health on the prevalence of sleep complaints amongst current and retired athletes
por: Montero, A, et al.
Publicado: (2022)

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae
por: Crandon, Jared L., et al.
Publicado: (2015)

Comparative risk factors for nosocomial New Delhi metallo-beta-lactamase (NDM-1) producing Enterobacteriaceae and non-carbapenemase producing (NCP) Enterobacteriaceae
por: Izharuddin, E, et al.
Publicado: (2015)

Prevalence of ESBL-producing Enterobacteriaceae in raw vegetables
por: Reuland, E. A., et al.
Publicado: (2014)

Prevalence and antibiotic resistance of the ESBL producing enterobacteria strains isolated in Bologhine hospital during the years 2007-2010
por: Amhis, W, et al.
Publicado: (2011)

1425. "Influence of outpatient antibiotic prescriptions in prevalence of ESBL producing Enterobacteriaceae in local hospitals"
por: Ponce, Rafael, et al.
Publicado: (2023)

Molecular Characterization of ESBL-Producing Enterobacteriaceae in Northern Portugal
por: Fernandes, Rúben, et al.
Publicado: (2014)

Rapid Detection of ESBL-Producing Enterobacteriaceae in Blood Cultures
por: Dortet, Laurent, et al.
Publicado: (2015)

Activity of Ceftolozane/tazobactam (C/T) and Ceftazidime/avibactam (CZA) against Extended-spectrum Β-lactamase (ESBL)-producing Enterobacteriaceae and Multidrug-resistant (MDR) Pseudomonas aeruginosa Isolates
por: Hirsch, Elizabeth B, et al.
Publicado: (2017)

P081 Assessment of Change in Palatoglossus Length with Mandibular Advancement and Relationship to Response to Mandibular Advancement Splint Therapy in Obstructive Sleep Apnoea
por: Lim, K, et al.
Publicado: (2021)

55. Impact of Testing Methodology and Reporting on Time to Preferred Antibiotic Therapy in Extended Spectrum Beta-Lactamase producing Enterobacteriaceae (ESBL-E) Bloodstream Infections
por: Bui, Hanh, et al.
Publicado: (2021)

1306. Comparison of the Use of Extended and Intermittent Infusion Cefepime and Piperacillin/tazobactam in Non-critically Ill, Obese Patients
por: Marg, Carolyn, et al.
Publicado: (2020)

1612. Evaluation of the Use of Ceftolozane/Tazobactam for the Treatment of ESBL-producing Enterobacterales Infections Using International Data from SPECTRA (Study of Prescribing Patterns and Effectiveness of Ceftolozane/Tazobactam Real World Analysis)
por: Soriano, Alex, et al.
Publicado: (2020)

1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β-Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model
por: Lasko, Maxwell J, et al.
Publicado: (2020)

AB081. Effects of combination therapy of Tamoxifen, L-carnitine and daily PDE5 inhibitors in the Peyronie’s disease
por: Kang, Jae Il, et al.
Publicado: (2016)

50. Comparative Incidence of Acute Kidney Injury in Septic Patients Treated with Vancomycin in Combination with Piperacillin/Tazobactam vs. Cefepime
por: Deja, Erin, et al.
Publicado: (2020)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective
por: Brolund, Alma
Publicado: (2014)

Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam
por: Reuland, E. A., et al.
Publicado: (2016)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

Combination Therapy with Aminoglycoside in Bacteremiasdue to ESBL-Producing Enterobacteriaceae in ICU
por: Benetazzo, Lucie, et al.
Publicado: (2020)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

839. Epidemiology of Extended-Spectrum Beta-lactamase (ESBL) Producing Enterobacteriaceae in the South East Tennessee, October-December 2017
por: Muleta, Daniel, et al.
Publicado: (2020)

Emerging MDR producing ESBL among Diarrhoegenic Esherichia coli from paediatric patients
por: Pinto, Ashita A, et al.
Publicado: (2014)

Antibiotic Exposure during the Preceding Six Months Is Related to Intestinal ESBL-Producing Enterobacteriaceae Carriage in the Elderly
por: Zhang, Man, et al.
Publicado: (2022)

A Comparison Between Cefepime and Piperacillin-Tazobactam in the Management of Septic Shock
por: Ross, Robert C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cru0dnm0cs96va96q5f28aufja